A Phase 1b, Multi-center, Open-label, Dose Finding Study of CC-122 in Combination With Sorafenib in Subjects With Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Avadomide (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 17 Mar 2017 Status changed from recruiting to discontinued.
- 20 Apr 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.
- 18 Aug 2015 Planned number of patients changed from 45 to 40 as reported by ClinicalTrials.gov record.